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INTRODUCTION
Metallothionein (MT) family is a class of low 
molecular mass, intracellular, cysteine-rich proteins with 
a high affinity to metals. Total MTs were firstly isolated 
from horse kidney and characterized by Margoshes and 
Vallee [1]. All vertebrates examined contain at least two or 
more distinct MT isoforms designated MT-1 through MT-
4. MT-3 was originally dubbed neuronal growth-inhibitory 
factor (GIF) due to its neuroinhibitory activity [2]. Besides, 
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ABSTRACT
Human metallothionein-3 (hMT-3), also known as growth inhibitory factor, 
is predominantly expressed in the central nervous system. hMT-3 is presumed to 
participate in the processes of heavy metal detoxification, regulation of metabolism 
and protection against oxidative damage of free radicals in the central nervous 
system; thus, it could play important neuromodulatory and neuroprotective roles. 
However, the primary functions of hMT-3 and the mechanism underlying its multiple 
functions in neuroblastoma have not been elucidated so far. First, we confirmed 
relatively high expression of hMT-3 encoding mRNA in biopsies (n = 23) from high-
risk neuroblastoma subjects. Therefore, we focused on investigation of the impact 
of hMT-3 up-regulation in N-Myc amplifying neuroblastoma cells. The differentially 
up-regulated genes involved in biological pathways related to cellular senescence 
and cell cycle were identified using electrochemical microarray with consequent 
bioinformatic processing. Further, as experimental verification of microarray data, 
the cytotoxicity of the cisplatin (CDDP) was examined in hMT-3 and mock cells by 
MTT and clonogenic assays. Overall, our data strongly suggest that up-regulation of 
hMT-3 positively correlates with the genes involved in oncogene-induced senescence 
(CDKN2B and ANAPC5) or apoptosis (CASP4). Moreover, we identified a significant 
increase in chemoresistance to cisplatin (CDDP) due to hMT-3 up-regulation (24IC50: 
7.5 vs. 19.8 µg/ml), indicating its multipurpose biological significance.
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MT-3 might also participate in the processes of metal 
detoxification, metabolism regulation, and protection 
from damage caused by oxidative free radicals in central 
nervous system (CNS) [3]. In the past few years, MT-3 had 
been postulated to be a multipurpose protein, which could 
play important neuromodulatory and neuroprotective roles 
in CNS besides the common roles of MTs [4], including 
those connected with neurodegenerative diseases [5]. 
MT-3 shows a brain-specific expression, mainly in 
glutamatergic neurons; however, up-regulation of these 
proteins has also been found in a number of cancers, 
where its presence positively correlates with the poor 
survival prognosis [6]. 
Neuroblastoma (Nbl) is a malignancy of the 
sympathetic ganglia and adrenal medulla, structures 
derived from the embryonic neural crest. It is the most 
common extracranial solid cancer in children younger than 
5-years and the most common cancer in infants [7–10]. 
Although, the connection between CNS cancers and 
MT-3 was already described (e.g. up-regulation and poor 
survival for glioblastoma multiforme [11]), the primary 
function of MT-3 and the mechanisms underlying its effect 
on gene expression in Nbl were not elucidated so far. 
Cisplatin or cis-diamminedichloroplatinum (CDDP) 
is one of the most commonly used drugs in the treatment 
of Nbl [12], inducing cytotoxic cell death mediated by 
activation of death receptor-mediated apoptotic signaling 
mechanisms as well as mitochondrial pathways [13, 14]. 
This reactive drug interacts not only with DNA but also 
with proteins. One of the current accepted opinions states 
that damage to various cytoplasmic proteins is an early 
process that initiates CDDP-induced apoptosis [15, 16]. 
It is worth noting that the concentration of MTs increases 
in the moment of administration of the platinum-based 
drugs. Such stimulated MTs can also rapidly bind the 
administered CDDP, which can result in decrease of drug 
concentration below the effective level [17, 18].
To date, as far as we are aware, no information 
concerning the complex role of MT-3 in Nbl cells exists. 
Therefore, to unravel the putative mechanisms involved in 
influencing of enhanced expression of human MT-3 (hMT-3) 
in Nbl cells, we carried out comparative screening of gene 
expression by cDNA microarray. We utilized SiMa cell 
line derived from high-risk Nbl with N-Myc amplification 
and loss of chromosome 11, which is a well-characterized 
model of human neuronal growth and differentiation 
[19]. To increase the expression of hMT-3 we transiently 
transfected SiMa cells with a plasmid containing hMT-3 
gene (pcDNA3.1-GFP-hMT-3-TOPO) or with an empty 
vector (pcDNA3.1-GFP-TOPO). The main aim was to 
promote novel insights into the molecular mechanisms of 
hMT-3 up-regulation and to elucidate the effects beneath 
the hMT-3 up-regulation in Nbl cells. Hence, we performed 
comparative microarray survey with a special emphasis on 
expression of genes driving pivotal cancer-related molecular 
pathways. Moreover, we also focused on experimental 
verification of the hypothesis that hMT-3 is able to increase 
chemoresistance of Nbl cells to CDDP. 
RESULTS
hMT-3 expression in Nbl biopsies and non-
malignant cell lines derived from adrenal cortex
In order to verify that Nbl expresses hMT-3, 
we examined 23 high-risk (HR) Nbl specimens and 
quantified hMT-3 expression. Patient data are shown in 
Supplementary Table 1. All samples expressed hMT-3 
within the range of 2-∆∆Ct 12.550–19.245. Although we 
did not show any significant relationship to the prognosis, 
amplification of N-Myc, or whether a sample was taken 
before or during chemotherapy, it is worth to note that 
high-risk Nbl express relatively high amount of mRNA 
encoding hMT-3. As Nbl mostly starts from one of the 
adrenal glands, we further investigated hMT-3 expression 
in non-malignant cell lines derived from adrenal cortex. 
Noteworthy, we found that normal adrenal cortex-derived 
cells express mRNA encoding hMT-3, which is in good 
agreement with study by Felizola et al. [20]. However, 
the 2-∆∆Ct values were considerably lower (0.699–2.365) 
compared with HR Nbl specimens. Overall, these findings 
underpin an importance of hMT-3 in Nbl. This prompted 
us to continue with isolation and cloning of hMT-3 for 
consequent transfections, followed by microarray survey 
and phenotypic analyses.
Transfection of SiMA cells with pcDNA3.1-GFP-
hMT-3-TOPO (hMT-3) or pcDNA3.1-GFP-
TOPO (mock)
Figure 1A demonstrates the efficiency of 
transfection analysed through a fluorescence of GFP 
tag expressed at the C-terminus of hMT-3. The results 
show that our optimized transfection protocol resulted in 
approx. 70% transfection efficiency for both constructed 
plasmids (mock and hMT-3). An ambient and fluorescence 
microscopy revealed formation of large bright-green GFP 
aggregates in mock cells and in lesser content also in 
hMT-3 counterparts (Figure 1B and Figure 1C).
Further, the qRT-PCR confirmed significant (p < 
0.05) increase in the expression of hMT-3 (Figure 1D). 
In this case, 2–ΔΔCT method revealed that the transfection 
with hMT-3 resulted in 8-fold higher relative expression 
compared with WT SiMa cells or mock cultures. Finally, 
Western blotting with rabbit anti-MT-3 antibody confirmed 
pronouncedly increased expression of hMT-3 in the hMT-
3 transfected SiMa extract, while mock transfection 
showed comparable hMT-3 expression to that of WT cells 
as shown in Figure 1E.
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hMT-3 up-regulation in SiMa cells influences 
expression of genes involved in oncogene-
induced senescence (OIS) and cell cycle
We investigated the cancer-related genes affected 
by hMT-3 up-regulation using electrochemical microarray 
(expression heatmap is shown in Figure 2A). Table 1 
shows a list of genes, along with their accession numbers, 
which were found up- and down-regulated in three 
independent analyses (n = 3, the genes with Fold ratio > 
1.5, which were considered as significantly up-regulated, 
are displayed only). Our analyses revealed that hMT-3 up-
regulation induced up- or down-regulation of several genes 
(20 vs. 3, respectively). To confirm selected microarray 
results we separately performed semiquantitative (SQ) RT-
PCR of five selected genes with the highest expression 
(CSPG2, ANAPC5, PIAS2, BMP1 and ASPM) and 
MT-3. To adjust the amount of transcribed cDNA, 18S 
rRNA was selected as an internal control. Validation of 
microarrays by SQ-RT-PCR for selected genes is shown 
in Supplementary Figure 1. 
We further carried out the gene ontology (GO) 
analysis of involvement of the up-regulated genes within 
biological pathways related to regulation of biological 
functions, response to stimuli and homeostatic processes. 
Table 2 shows the list of processes and/or pathways of 
gene regulation in hMT-3 SiMa cells using GO annotations 
and KEGG 10 software, respectively. Noteworthy, the 
bioinformatic analyses revealed the up-regulation of 
numerous genes affecting biological pathways related 
to cellular senescence (schematized in Figure 2B) and 
OIS (Figure 2C). The OIS is a robust and sustained 
antiproliferative response brought by oncogenic signaling 
resulting from an activating mutation of an oncogene, 
or the inactivation of a tumor-suppressor gene [21–23]. 
We identified two major targets: i) CDKN2B (cyclin 
dependent kinase inhibitor 2B) and ii) ANAPC5 (anaphase 
promoting complex subunit 5), which belong to biological 
pathways related to OIS [24–26]. We also identified 
increase in glutathione S-transferase M3 (GSTM3), which 
is a member of the superfamily of GST enzymes and 
which may correspond to the initiation of self-protective 
machinery of cells in tumorigenetic process [27]. 
Among others, CASP4 (caspase-4) plays role in 
sequential activation of caspases, which is a central role 
in the execution-phase of cell apoptosis [28]. DNAJB6 
[DnaJ heat shock protein family (Hsp40) member B6] is 
involved in a wide range of cellular events, such as protein 
folding and oligomeric protein complex assembly and has 
a relevant functional role in neurons [29]. 
We also performed analysis of hMT-3 effect on 
migration of hMT-3 vs. mock cultures. Figure 2D and 2E 
illustrate that hMT-3 up-regulation significantly (p < 0.05) 
decreased the migration of transfected cells.
Overall, we show that hMT-3 has a significant 
biological role affecting regulatory pathways, which could 
pronouncedly influence the susceptibility of cancer cells 
to chemotherapy. It must be mentioned that our results 
are based on gene expression, which can be biased due 
to various aspects of cellular biology (e.g. by epigenetic 
silencing and subsequent translational repressions). Hence, 
we also focused on experimental verification of obtained 
Figure 1: Comparison of WT, mock and hMT-3 neuroblastoma (SiMa) cells. The cells were transfected with either pcDNA3.1-
GFP-TOPO (mock transfection) or pcDNA3.1-GFP-hMT3-TOPO (hMT-3). Transfection efficiency and cells viability was estimated by 
(A) fluorescence cell counting, (B) ambient and (C) fluorescence microscopy. For comparison, non-transfected - wild-type (WT) cells are 
included. The length of scale bar is 30 µm. (D) qRT-PCR showing changes in mRNA encoding hMT-3. Data were analyzed by comparative 
CT method and presented as relative fold gene expression (2
–ΔΔCT). (E) Representative immunoblots analyses of whole-cell lysates evaluated 
for hMT-3 expression. GAPDH served as loading control. Data with asterisk (*) indicate statistical significance (p < 0.05).
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results in terms of evaluation of impact of hMT-3 up-
regulation on cytotoxic effects of CDDP.
hMT-3 causes pronounced resistance to cytotoxic 
activity of CDDP 
As an experimental verification of microarray data, 
showing involvement of hMT-3 into OIS and cell cycle 
regulation, the susceptibility to CDDP was examined 
using the MTT and clonogenic assays. As shown in 
Figure 3A, CDDP induced toxic effects in both hMT-
3 and mock cultures. Despite that, we found significant 
differences in cell viability, highlighted by survival curves 
(Figure 3A) and by calculated 24IC50, which were 7.5 µg/
ml vs. 19.8 µg/ml (mock vs. hMT-3, respectively). Due to 
the fact that MTT reagent can be significantly influenced 
by assay conditions and estimates more metabolic activity, 
not necessarily viability, we decided to carry out validation 
by clonogenic assay, which is a standard technique for 
studying the effects on the cells survival and proliferation. 
Figure 3B illustrates that clonogenic assay corroborated 
our previous results and that hMT-3 significantly 
influences chemoresistance of SiMa cells against CDDP. 
Moreover, Figure 3C depicts that hMT-3 cells reached 
lower initial confluence and had lower proliferative 
rate, which is in agreement with wound-healing assay 
(Figure 2D and 2E) and which could be explained by up-
regulation of OIS-related genes. 
In addition to these data, Figure 3D demonstrates 
that hMT-3 up-regulation caused pronounced decrease 
in cleaved caspase-3, which is activated by both 
extrinsic and intrinsic apoptotic signals. Moreover, 
Figure 3E demonstrates that up-regulated hMT-3 acts 
as a scavenger of CDDP-induced intracellular reactive 
oxygen species (ROS). Overall, these data are in good 
agreement with lower susceptibility of hMT-3 SiMa 
Figure 2: Comparative bioinformatical processing of microarray data. (A) Representative microarray heatmaps showing gene 
expressions in SiMa cells (one spot per one gene). Gray scale intensity represents the rate of individual mRNA expression. (B) hMT-3 
induced over-expression of genes was identified to affect the regulation of cellular senescence pathway (data were analyzed by Reactome, 
http://www.reactome.org/). (C) Schematic drawing of oncogene-induced senescence pathway. Black framings indicate genes identified as 
up-regulated after hMT-3 transfection. (D) Representative micrographs of wound-healing assay showing slower migration of hMT-3 cells. 
Micrographs demonstrate the artificial wounds at the experimental start-point (0 h) and the migration of the cells after 48 h incubation. 
The length of scale bar is 100 µm, n.d. not detected. (E) Quantitation of relative free areas. The values are expressed as the mean of six 
independent replicates (n = 6). Data with asterisks (*) indicate statistical significance (p < 0.05).
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cells to CDDP and highlight the importance of hMT-3 
in Nbl biology.
DISCUSSION
In recent studies, MT up-regulation has been linked 
with the enhanced cell proliferation in human tumors of 
breast, colon, kidney, liver, lung, nasopharynx, ovary, 
prostate and testes [30–34]. Dziegiel et al. showed that 
up-regulation of MT in various malignant tumors could 
be suggested as a potential factor of poor prognosis [35]. 
Contrary to that, the current studies in the androgen-
independent prostate cancer cells demonstrate that the 
endogenous up-regulation of MT-3 can inhibit cell 
growth [36]. Nevertheless, to the best of our knowledge 
there is a lack of information regarding MT-3 role in 
Nbl cells. In our initial experiments, we found that 
despite their chemoresistance to CDDP, hMT-3 cells 
Table 1: List of genes up- or down-regulated after transfection with hMT-3 or in mock culture
hMT-3 vs. mock
Up-regulation
Gene Symbol NCBI database Fold ratio SD  (n = 3)
Chondroitin sulfate proteoglycan 2 CSPG2 NM_004385 2.947 3.451
Anaphase promoting complex subunit 5 ANAPC5 NM_016237 2.670 0.201
Protein inhibitor of activated STAT, 2 PIAS2 NM_173206 2.089 0.537
Bone morphogenetic protein 1 BMP1 NM_001199 1.872 0.438
Asp (abnormal spindle)-like, microcephaly associated ASPM NM_018136 1.804 0.145
L-3-hydroxyacyl-Coenzyme A dehydrogenase, short 
chain HADHSC NM_005327 1.672 0.201
Cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4) CDKN2B NM_004936 1.653 0.064
Glutathione S-transferase M3 GSTM3 NM_000849 1.646 0.220
Centromere protein A, 17kDa CENPA NM_001809 1.605 0.288
Caspase 4, apoptosis-related cysteine peptidase CASP4 NM_001225 1.586 0.045
Hypothetical protein FLJ12443 FLJ12443 NM_024830 1.582 0.229
Small nuclear ribonucleoprotein polypeptides B and 
B1 SNRPB NM_003091 1.578 0.426
Plasminogen activator, tissue PLAT NM_033011 1.544 0.004
DnaJ (Hsp40) homolog, subfamily B, member 6 DNAJB6 NM_058246 1.542 0.137
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 DDX21 NM_004728 1.540 0.147
Pre-B-cell colony enhancing factor 1 PBEF1 NM_005746 1.538 0.075
Lactate dehydrogenase B LDHB NM_002300 1.524 0.497
Sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3B SEMA3B NM_001005914 1.523 0.026
Metallothionein 3 MT3 NM_005946 1.520 0.018
Palmitoyl-protein thioesterase 1 (ceroid-
lipofuscinosis, neuronal 1, infantile) PPT1 NM_000310 1.504 0.016
Down-regulation
Gene Symbol NCBI database Fold ratio SD  (n = 3)
Histone deacetylase 2 HDAC2 NM_001527 0.470 0.315
X-ray repair complementing defective repair 3 XRCC3 NM_005432 0.458 0.162
CD47 antigen (Rh-related antigen, integrin-associated 
signal transducer) CD47 NM_001025079 0.114 0.0109
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reached full confluence much slower than mock cells. 
This corroborates well-known fact that MT-3 acts as 
neuronal growth inhibitory factor [37] and corresponds 
to the identified up-regulation of OIS-related genes. 
Moreover, hMT-3 inhibits cell migration as demonstrated 
by experiments with artificial wounds. 
Our microarrays shed some light on the genes 
involved in inducing senescence in tested Nbl cells with 
up-regulated hMT-3. Organisms with renewable tissues 
had to evolve mechanisms to prevent the development of 
cancer. One such mechanism is cellular senescence, which 
irreversibly arrests the growth of cells at risk for neoplastic 
transformation [38]. Cellular senescence, a growth-arrest 
program that limits the lifespan of mammalian cells 
and prevents unlimited cell proliferation, is attracting 
considerable attention because of its links to tumor 
suppression [39, 40].
Cyclin-dependent kinase 4 inhibitor B, also known 
as multiple tumor suppressor 2 (MTS-2) or p15INK4B, 
is a protein encoded by the CDKN2B gene in humans. 
CDKN2B gene encodes 2 distinct transcript variants: 
p15 and p10. The CDKN2B/p15 gene plays a critical 
role in cell cycle progression and is considered to be 
a target for tumor inactivation in Nbl cells [41]. Our 
results showed that CDKN2B was up-regulated in hMT-3 
cells. A component of the anaphase promoting complex 
(APC), a cell cycle-regulated E3 ubiquitin ligase controls 
progression through mitosis and the G1 phase of the cell 
cycle. Park et al. showed a negative correlation between 
APC expression and a high grade with aneuploidy 
supports a possible linkage between the downregulation of 
APC and malignant transformation in breast cancer [42]. 
Now, the regulation of APC in Nbl cells is not sufficiently 
known. However, our results showed that the anaphase 
promoting complex subunit 5 (ANAPC5) was up-regulated 
due to hMT-3 transfection.
GST is abundantly expressed in some mammalian 
tissues, particularly those associated with malignancies. 
GSTs have been found to have regulatory roles via 
kinase interactions and subsequent downstream control 
of cell proliferation, inflammatory responses, apoptosis 
and senescence. Enough recent evidences suggest that 
pharmacological inhibition of these enzymes may be 
useful for the treatment of cancer and other diseases 
associated with aberrant cell proliferation [43]. GSTs may 
be associated with resistance to a range of cytotoxic drugs, 
some of which are commonly used to treat Nbl cells [44]. 
Since most cancer drugs are not good substrates for GSTs, 
the question of why cells with acquired drug resistance 
have such high levels of this isozyme seems perplexing. 
Moreover, even without drug selection, GSTs can be one 
of the more prevalent cytosolic proteins in cancer cells. 
These observations would seem to indicate that GSTP has 
a diversity of functions in cancer cells, some of which are 
likely unrelated to the detoxification of chemicals or drugs 
[45]. The significant increase of GSTM3 level in Nbl 
cells may correspond to the initiation of self-protective 
machinery of cells in tumorigenetic process [27, 46]. 
Table 2: The list of processes and/or pathways involved in gene regulation in SiMa cells (hMT-3 vs. mock) using gene 
ontology (GO) annotations and KEGG 10 software
hMT-3 vs. mock
Up-regulation
pathway ID pathway description observed gene count
false discovery 
rate
GO.0007094 mitotic spindle assembly checkpoint 5 1.07E-06
GO.0070979 protein K11-linked ubiquitination 5 1.07E-06
GO.0007093 mitotic cell cycle checkpoint 6 2.32E-05
GO.0009896 positive regulation of catabolic process 8 2.35E-05
GO.0031145 anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process 5 2.35E-05
GO.0045861 negative regulation of proteolysis 7 4.65E-05
GO.1903047 mitotic cell cycle process 8 0.0003
GO.0000278 mitotic cell cycle 8 0.0006
Down-regulation
pathway ID pathway description observed gene count
false discovery 
rate
GO:0007155  ECM-receptor interaction 1 0.0139
GO:0043044 Notch signaling pathway 1 0.0012
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Our results further revealed that also caspase-4 
(CASP4) was up-regulated in hMT-3 cells. CASP is a 
family of endoproteases that provides critical links in cell 
regulatory networks controlling apoptosis. Dysregulation 
of caspases underlies human diseases including cancer 
and inflammatory disorders, and major efforts to design 
better therapies for these diseases seek to understand how 
these enzymes work and how they can be controlled [47]. 
Sequential activation of caspases plays a central role in the 
execution-phase of cell apoptosis. Yang et al. suggested 
that CASP4 activity is required for Fas-induced cell 
apoptosis and indicated that CASP4 is a new mediator of 
NF-κB pro-apoptotic pathway in Nbl cells [28]. Overall, 
it is worth noting that hMT-3 up-regulation had crucial 
biological effects in vitro and resulted in phenotype with a 
lower proliferative rate and aggressiveness. This indicates 
that contrary to other MT subtypes and CNS cancer [11, 
48]; hMT-3 should not be connected with worst prognosis 
or outcome of patients with Nbl. To fully prove this 
phenomenon, experiments studying the amount of MT-3 
in biopsies and sera of Nbl subjects are on the way.
Relapse disease with the emergence of drug resistant 
tumor cells is a major impediment to the successful 
treatment of high-risk Nbl patients. The mechanisms 
responsible for CDDP resistance are several, and contribute 
to the multifactorial nature of the problem [49]. Based on 
many clinical studies, it is well known that a resistance to 
a treatment by cytostatic agents is a crucial complication 
of anticancer therapy [17]. As in some clinical settings 
CDDP constitutes the major therapeutic option, the 
development of chemosensitization strategies constitutes 
a goal with important clinical implications [50, 51]. 
In general, multiple mechanisms have been identified 
for the acquisition of drug resistance by cancer cells, 
including: inhibition of apoptosis through activation of 
the PI3-K/AKT pathway and induction of antiapoptotic 
Bcl-2 family members, loss of p53 function resulting in 
altered apoptosis induced by platinum-DNA lesions, and 
up-regulation of ABC family members causing the efflux 
of CDDP from the cell [52]. Florea et al. showed that one 
of the intracellular mechanisms of acquired resistance 
to CDDP increases detoxification of drugs by the thiols 
glutathione and MTs [53]. Once inside the cell, it interacts 
with MTs that sequester CDDP and remove it from the 
cell. Therefore, MT may contribute to CDDP resistance. In 
some cases, the levels of MT are higher in CDDP-resistant 
cells, but in other cases, the MT levels are unaffected [54]. 
Our results showed that up-regulated hMT-3 pronouncedly 
increased the resistance to CDDP. 
Iolascon et al. demonstrated, for the first time, that a 
significant percentage of Nbl cells lack caspase-3 mRNA 
and protein [55]. Although, our microarray expression 
Figure 3: Investigation of hMT-3 up-regulation on cytotoxicity of CDDP. (A) MTT survival curves of mock and hMT-3 cells 
exposed to CDDP (1.2–20.0 µg/ml) for 24 h. Inserted are 24IC50 values for both tested cell lines. (B) Percentage of survival after application 
of CDDP determined by clonogenic assay. Data with asterisk (*) indicate significant differences (p < 0.05). (C) Detailed representative 
micrographs of clonogenic assay plates showing significant differences between mock and hMT-3 cells survival and also clonogenicity. 
The length of scale bar is 200 µm. The cells were stained with 0.1% crystal violet. (D) Estimation of apoptotic markers in mock and hMT-
3 cultures after CDDP treatment. β-actin served as loading control. (E) Living cell microscopy of CDDP-induced ROS (CellROX, red). 
Nuclei were counterstained with Hoechst 33258. The length of scale bar is 20 µm.
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data did not show effect of hMT-3 on caspase-3, 
immunoblotting revealed that cultures with up-regulated 
hMT-3 expressed significantly decreased amount of 
cleaved caspase-3 compared with mock cultures. We 
anticipate that the decrease in cleaved caspase-3 is mostly 
associated with an enhanced binding of CDDP to hMT-
3 structure. Up-regulated hMT-3 also scavenges CDDP-
induced ROS as shown in Figure 3E. These mechanisms 
consequently contribute to inhibition of apoptosis and 
decreased requirements for pro-caspase-3 cleavage.
The MTT and clonogenic assays results could shed 
some light on the MT-3 involved in inducing resistance 
to CDDP in cancer cells. These data strongly suggest 
that up-regulated hMT-3 potently induces properties of 
Nbl cells and their chemoresistance to CDDP, revealing 
great potential for its further investigation by means 
of prognostic biomarker. We anticipate that increased 
expression of hMT-3 within tumor mass should inform 
about worse prognosis and also decreased efficiency 
of platinum-based chemotherapy. However, further 
investigations of this phenomena might be done.
MATERIALS AND METHODS
Chemicals
All chemicals and reagents were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) in ACS purity, 
unless noted otherwise.
Tumor tissue and blood samples collection
The high-risk Nbl tissue samples obtained from 
positive biopsies were collected from 23 patients at 
University hospital Motol, Prague, Czech Republic from 
January 2003 to December 2013. 
Patients’ data are summarized in Supplementary 
Table 1. Samples were frozen within 1 h after surgery 
and were stored in liquid nitrogen until RNA was isolated 
using High pure total-RNA isolation kit (Roche, Basel, 
Switzerland). Clinical part of this study was approved by 
the Ethics Committee of University hospital Motol. In 
case of Nbl specimens, informed consent was obtained 
from all parents of patients. 
Cell lines and culture conditions
For transfections and microarray experiments, SiMa 
(N-Myc amplified) cell line established from the adrenal 
tumor tissue resected after treatment from a 20-month-old 
boy of European origin with stage III Nbl was employed. 
We further used following cell lines to evaluate the 
expression of hMT-3 in non-malignant cells: i) HAdCC 
(human adrenal cortical cells), primary cell line isolated 
from normal human adrenal cortical tissue, ii) EJG derived 
from collagenase dissociated bovine adrenal tissue and iii) 
SBAC which is a non-malignant cell type with fibroblast 
morphology derived from adrenal cortex. Except for 
HAdCC, all cell lines were purchased from American Type 
Culture Collection (Manassas, VA, USA). HAdCC cells 
were bought from ScienCell (Carlsbad, Ca, USA). SiMa 
cells were cultured in RPMI-1640, GlutaMAX, with 10% 
heat inactivated fetal bovine serum (FBS), EJG cells were 
cultured in MEM with 10% FBS and SBAC cells were 
cultured in Ham´s F12 with fibroblast growth factor (40 ng/
ml) and 10% FBS. HAdCC cells were resuscitated, thawed, 
and cultured to 3–10 passages in MSCM with 10% FBS. 
All media were supplemented with penicillin (100 U/ml) 
and streptomycin (0.1 mg/ml) and cells were cultured in a 
humidified atmosphere containing 5% CO2 at 37°C.
DNA constructs and cell transfection 
Isolated human MT-3 gene (hMT-3) was cloned in 
the pRSET-B vector (Invitrogen, Waltham, MA, USA, 
Supplementary Figure 2A). The chemical transformation 
protocol was performed following the instructions of New 
England Biolabs (Ipswich, MA, USA), using BL21(DE3)
pLysS chemically competent Escherichia coli as a host. 
The amplified plasmid was further isolated by using the 
Qiagen Miniprep Kit (Qiagen, Germantown, MD, USA). 
Then, the hMT-3 gene was amplified by Expand High 
Fidelity PCR System. The PCR product was cloned into 
NT-GFP fusion TOPO® TA (Invitrogen) expression vector 
(Supplementary Figure 2B). The chemical transformation 
protocol was performed following the instructions of 
New England Biolabs, using BL21(DE3)pLysS as a host 
to obtain pcDNA3.1-GFP-hMT-3-TOPO. The positive 
transformants of hMT-3 were grown in Luria-Bertani 
broth with 50 µg/ml ampicillin. The orientation of the 
hMT-3 sequence within the cloning vector was checked 
by Sanger sequencing (Promega, Madison, WI, USA) 
(Supplementary Figure 2C). SiMa cells were transfected 
with pcDNA3.1-GFP-hMT-3-TOPO encoding full-length 
hMT-3. An empty pcDNA3.1-GFP-TOPO was used as 
the mock control. SiMa cells were incubated on 6-well 
plate: 1 × 106; for 24 h at 37°C. Then, 200 µl of medium 
containing 3 µg of pcDNA3.1-GFP-hMT-3-TOPO or 
pcDNA3.1-GFP-TOPO as control (mock transfection) 
and 3 µg of polyethyleneimine (PEI) was added and the 
cells were incubated for another 12 h. After incubation, 
the medium was replaced with new medium and the cells 
were incubated for another 24 h. Then, the transfection 
efficiency was monitored by Countess FL II (Thermo 
Fisher Scientific, Waltham, MA, USA) and fluorescence 
microscopy (Olympus IX 71S8F-3 (Olympus, Tokyo, 
Japan) using the fluorescence of green fluorescence 
protein (GFP). 
Isolation of RNA and reverse transcription (RT)
High pure total-RNA isolation kit (Roche, Basel, 
Switzerland) was used for isolation of cellular RNA. 
The medium was removed and samples were washed 
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twice with 5 ml of ice-cold PBS. Cells were scraped 
off, transferred to clean tubes and centrifuged at 
20 800 × g for 5 min at 4°C. After that, lysis buffer was 
added and RNA isolation was carried out according to 
manufacturer’s instructions. Similarly, RNA from biopsies 
was isolated using the same kit. Isolated RNA was used 
for cDNA synthesis. RNA (500 ng) was transcribed using 
Transcriptor First Strand cDNA Synthesis Kit (Roche) 
according to manufacturer’s instructions. Prepared cDNA 
(20 µl) was diluted with RNase-free water to a total 
volume of 100 µl and 5 µl of this solution was employed 
for qRT-PCR and microarrays.
qRT-PCR of hMT-3 encoding mRNA
Gene expression was studied by qRT-PCR using 
the SYBR Green Quantitative RT-PCR Kit and the 
Mastercycler pro S instrument (Eppendorf, Hamburg, 
Germany). The specificity of the q-RT-PCR was checked 
by melting curve analysis and the relative levels of 
transcription were calculated using the 2−ΔΔCT method. 
Further, the SQ-RT-PCR was checked on 1% agarose 
gel electrophoresis. The list of primers for validation of 
microarray by SQ-RT-PCR is shown in the Supplementary 
Table 2. SQ-RT-PCR experiments were performed in 
conditions described in our previous study [56].
Western blotting
The cells were harvested by trypsinization and then 
centrifuged at 10 000 rpm for 10 min. The lysis was done 
on ice with 200 µl of RIPA lysis buffer containing 2 µl of 
protease inhibitor cocktail. Extracted protein was stored 
at −80°C until analyzed. Equal amounts of protein were 
separated using SDS-PAGE and then electroblotted onto 
a PVDF membrane. The PVDF membrane was blocked 
with 1% skimmed milk in PBS (37 mM NaCl, 2.7 mM 
KCl, 1.4 mM NaH2PO4, 4.3 mM Na2HPO4, pH 7.4) and 
then incubated separately with primary antibodies against 
MT-3 (1:200) or GAPDH (1:750) at 4°C overnight. Next, 
the membrane was incubated with peroxidase-conjugated 
secondary antibodies (1:1000) for 1 h at 25°C. For analysis 
of apoptotic markers, we used Apoptosis Western Blot 
Cocktail assay (Abcam, Cambridge, UK) following the 
manufacturer´s instructions. The bands were developed 
using a 3-amino-9-ethyl-carbazole and hydrogen peroxide. 
Finally, blots were washed and visualized using Azure 
c600 (Azure Biosystems, Dublin, CA, USA).
Electrochemical microarray
The obtained cDNA was biotinylated on its 3′ end 
using the Biotin 3′ End DNA Labeling Kit (Thermo Fisher 
Scientific) following the manufacturer’s instructions. 
The microarray analyses were performed as previously 
described by Roth et al. [57–59]. For hybridization, 
Human Cancer 3711 ElectraSense medium density 4 × 
2k array slides with 1,609 DNA probes (Custom Array, 
Bothell, WA, USA) were firstly pre-hybridized for 30 
min at 50°C using 6× SSPE (0.9 M NaCl, 60 mM sodium 
phosphate, 6 mM EDTA), 5× Denhardt´s solution and 
sonicated salmon sperm DNA (100 µg/ml). Then, the 
hybridization of biotin-labeled cDNA was performed at 
50°C for 18 h in 6× SSPE and salmon sperm DNA (100 
µg/ml). Array chips were rinsed with low ionic strength 
3× SSPET (3× SSPE, 0.05% Tween-20) and PBST (2× 
phosphate-buffered saline, pH 7.4, 0.1% Tween-20) 
to remove weakly bound DNA. Subsequently, array 
chips were blocked with biotin blocking solution for 
15 min. Chips were then incubated for 30 min with 
poly-horseradish peroxidase-streptavidin (1:1000 in 
PBS containing 1% bovine serum albumin and 0.05% 
Tween-20). Next, chips were rinsed three times with 
biotin wash solution and TMB rinsing solution, followed 
by incubation with TMB substrate. Measurements were 
performed using the ElectraSense detection kit (Custom 
Array). All post-hybridization processing steps were 
performed at 25°C.
Wound-healing assay 
The cells were pipetted into 6-well plate to reach the 
confluence ~80%. After seeding of cells on the bottom of 
a plate, a pin was used to scratch and remove cells from a 
discrete area of the confluent monolayer to form a cell-free 
zone. After that, the cells were re-suspended in a fresh medium. 
After 48 h, the pictures of cells were taken and compared with 
pictures obtained at the start-point of experiment. The areas 
of wounds were analyses and quantified through Olympus IX 
71S8F-3 software (Olympus).
An effect of hMT-3 up-regulation on viability of 
CDDP-exposed Nbl cells - MTT assay
The viability was assayed using MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay. Briefly, the suspension of 5,000 cells in 50 µl medium 
was added to each well of microtiter plates, followed by 
incubation for 24 h at 37°C with 5% CO2 to ensure cell 
growth. After 24 h treatment, 10 µl of MTT (5 mg/ml in 
PBS) was added to the cells and the mixture was incubated 
for 4 h at 37°C. After that, MTT-containing medium was 
replaced by 100 µl of 99.9% dimethyl sulfoxide and after 5 
min incubation, absorbance of the samples was determined 
at 570 nm using Infinite 200 PRO (Tecan, Männedorf, 
Switzerland). All analyses were carried out in six replicates. 
Results are presented as percent of cell viability. Moreover, 
the viability was also analyzed by Trypan Blue Exclusion 
(0.4%) and automatically counted with Countess FL II 
instrument (Invitrogen).
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An effect of hMT-3 up-regulation on 
proliferation and survival of CDDP-exposed Nbl 
cells - Clonogenic assay 
Cells were seeded in a 6-well plate at a density of 
1 × 104 cells per well in a growth medium and incubated 
for 6 h. Then, the cells were treated with 5 µg/ml CDDP 
for 48 h. After medium renewal, the cells were incubated 
for 8 days. Finally, cells were washed with PBS and fixed 
using 500 µl of 3:1 methanol:acetic acid for 5 min. After 
fixing, the cells were stained using 500 µl of 0.5% crystal 
violet in methanol for 15 min. The survival fraction was 
calculated and related to survival of WT cells.
Fluorescence microscopy of ROS
Cells were cultivated directly on microscope glass 
slides (75 × 25 mm, thickness 1 mm, Thermo Fischer 
Scientific) in Petri dishes. After treatment (5 μg/ml of 
CDDP, 12 h), microscope glass slides with a monolayer 
of cells were removed from Petri dishes, rinsed with 
cultivation and directly used for analysis of ROS using 
CellROXTM Deep Red Reagent (Thermo Fisher Scientific) 
according to manufacturer’s instructions. For nuclei 
counterstaining, Hoechst 33258 was employed. Cells were 
visualized using the EVOS FL Auto Cell Imaging System 
(Thermo Fisher Scientific).
Descriptive statistics and exploited bioinformatic 
tools
For the statistical evaluation of the results, 
the mean was taken as the measurement of the main 
tendency, while standard deviation was taken as the 
dispersion measurement. Differences between groups 
were analyzed using paired t-test and ANOVA. Unless 
noted otherwise, the threshold for significance was 
p < 0.05. For analyses, Software Statistica 12 (StatSoft, 
Tulsa, OK, USA) was employed. The SIMA metabolic 
pathway was visualized using Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway database (http://
www.genome.jp/kegg/), which provides gold standard 
sets of molecular pathways. The involvement of genes 
involved in a cellular process was carried out using the 
Reactome (www.reactome.org).
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